Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Diabetes

    Evansville, IN

    Search
    Diabetes
    Evansville, IN
    Show Map
    Map View
    Evansville, IN
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      124 Diabetes Trials near Evansville, IN

      Power is an online platform that helps thousands of Diabetes patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Tirzepatide for Type 2 Diabetes

      Evansville, Indiana
      This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Pancreatitis, CVD, Others
      Must Be Taking:Metformin

      780 Participants Needed

      Tirzepatide for Pediatric Type 2 Diabetes

      Evansville, Indiana
      This trial is testing tirzepatide, a medication that helps control blood sugar levels, in children and teenagers with type 2 diabetes. These participants are already taking other diabetes medications like metformin or basal insulin. Tirzepatide works by helping the body use insulin more effectively and reducing sugar production in the liver. Tirzepatide is a new medication being tested for its effectiveness and safety in people with type 2 diabetes.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Age:10 - 18

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      99 Participants Needed

      Orforglipron for Type 2 Diabetes and Obesity

      Evansville, Indiana
      This trial is testing a new diabetes medication called orforglipron to see if it is safer and more effective than insulin in people with type 2 diabetes who are overweight or obese and at higher risk for heart problems. The study will last several years and involve multiple visits.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Pancreatitis, Others
      Must Be Taking:Oral Antihyperglycemics

      2749 Participants Needed

      CIN-102 for Gastroparesis

      Evansville, Indiana
      The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients. The main questions it aims to answer are: * To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with diabetic gastroparesis compared to a placebo * To evaluate the safety and tolerability of CIN-102 when given to patients with diabetic gastroparesis compared to a placebo Participants will go through the following schedule: * Screening period (1-2 visits) * Lead-in period (1 visit) * Will complete a Gastric Emptying Breath Test (GEBT) * Will complete daily diary and other Patient Reported Outcomes (PROs) as described in the protocol to assess eligibility for continued study participation * 12-week treatment period (7 visits) * Study drug taken twice daily by mouth * Will complete daily diaries and other PROs as described in protocol * 1 week follow-up (1 visit) Researchers will compare the effects of the following treatments: * Drug- CIN-102 Dose 15 mg or 10 mg * Drug- Placebo

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Non-diabetic Gastroparesis, Arrhythmia, Surgery, Others

      382 Participants Needed

      Cagrilintide for Obesity and Type 2 Diabetes

      Evansville, Indiana
      This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participant will either get cagrilintide or placebo. Which treatment participant get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. For each participant, the study will last for about 1 year and 6 months.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Others
      Must Be Taking:Oral Antidiabetics

      330 Participants Needed

      Retatrutide for Obesity

      Evansville, Indiana
      The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:45+

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Recent Heart Attack, Others

      10000 Participants Needed

      Retatrutide vs Semaglutide for Type 2 Diabetes

      Newburgh, Indiana
      The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Severe Hypoglycemia, Obesity Surgery, Others
      Must Be Taking:Metformin, SGLT2i

      1250 Participants Needed

      Bimagrumab + Tirzepatide for Obesity with Type 2 Diabetes

      Newburgh, Indiana
      The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 13 months.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Hypertension, Cardiovascular, Renal, Others
      Must Not Be Taking:Weight Loss Drugs

      180 Participants Needed

      Tirzepatide vs Dulaglutide for Type 2 Diabetes

      Owensboro, Kentucky
      The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:40+

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Severe Hypoglycemia, Pancreatitis, Malignancy, Others

      13299 Participants Needed

      Continuous Glucose Monitoring for Diabetes

      Owensboro, Kentucky
      The purpose of this study is to evaluate the effectiveness and safety of the RIGHTEST Continuous Monitoring (CGM) System in adult population with diabetes mellitus.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Kidney Disease, Cardiovascular Disease, Seizure Disorder, Others
      Must Not Be Taking:SGLT2 Inhibitors

      150 Participants Needed

      Inclisiran for Cardiovascular Disease Prevention

      Owensboro, Kentucky
      This trial tests whether inclisiran injections can prevent serious heart problems in high-risk adults who haven't had a major heart event yet by lowering their cholesterol levels. Inclisiran is a long-acting treatment that significantly lowers cholesterol.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:40 - 79

      Key Eligibility Criteria

      Disqualifiers:ASCVD, Revascularization, Liver Disease, Others
      Must Be Taking:Lipid Lowering

      14082 Participants Needed

      Vicadrostat + Empagliflozin for Type 2 Diabetes and Hypertension

      Owensboro, Kentucky
      This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin. Participants are put into 2 groups randomly, which means by chance. One group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets with empagliflozin. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants take a tablet once per day for 2 and a half years and up to 4 years and 3 months. All participants also continue their medication for type 2 diabetes, high blood pressure, and cardiovascular disease. Participants have an equal chance of receiving the study medicine or placebo. Participants are in the study for up to 4 years and 3 months. During this time, they visit the study site regularly. During these visits, doctors collect information about participants' health and take blood samples. The doctors document when participants experience cardiovascular events. The doctors also regularly check participants' health and take note of any unwanted effects.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Heart Failure, Atrial Fibrillation, Others
      Must Be Taking:Antihypertensives, Antidiabetics, Cardiovascular Drugs

      11800 Participants Needed

      Maridebart Cafraglutide for Obesity

      Paducah, Kentucky
      The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Pancreatitis, Severe Psychiatric Disorder, Others

      1105 Participants Needed

      NNC0487-0111 for Type 2 Diabetes

      Paducah, Kentucky
      The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Diabetic Retinopathy, Hypoglycaemic Unawareness, Others
      Must Be Taking:Metformin, SGLT2 Inhibitors

      432 Participants Needed

      Semaglutide for Diabetic Eye Disease

      Paducah, Kentucky
      This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - which treatment the participant gets is decided by chance. Participants will inject the study medicine using a pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. The study will last for 5 years.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Recent Heart Events, Severe Renal Impairment, Cancer History, Pregnancy, Others
      Must Not Be Taking:GLP-1 Agonists, DPP-4 Inhibitors

      1500 Participants Needed

      Peer Support for Type 2 Diabetes

      Bowling Green, Kentucky
      The goal of this clinical trial is to compare the effects of peer coaching models in older adults with unmanaged type two diabetes. The main questions it aims to answer are: Are peer coaching models effective at promoting Type 2 Diabetes Mellitus self-management? If effective, which facets of the peer model are most effective? Peer coaches will Undergo peer coach training. Reach out to peer participants on a weekly/biweekly time frame to discuss self-management and goal setting. Retain records of contact, topics discussed, and general notes on interactions. Researchers will compare differences in the frequency of contact, as well as how peer coaches were matched to peer participants to see if efficacy of the intervention is altered between groups.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:55 - 99

      Key Eligibility Criteria

      Disqualifiers:Age Under 55, Cognitive Impairment, Others

      76 Participants Needed

      Peer Support for Type 2 Diabetes

      Bowling Green, Kentucky
      The goal of this clinical trial is to compare the effects of peer coaching models in older adults with unmanaged type two diabetes. The main questions it aims to answer are: * Are peer coaching models effective at promoting Type 2 Diabetes Mellitus self-management? * If effective, which facets of the peer model are most effective? Peer coaches will * Undergo peer coach training. * Reach out to peer participants on a weekly/biweekly time frame to discuss self-management and goal setting. * Retain records of contact, topics discussed, and general notes on interactions. Researchers will compare differences in the frequency of contact, as well as how peer coaches were matched to peer participants to see if efficacy of the intervention is altered between groups.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:55+

      Key Eligibility Criteria

      Disqualifiers:Age Less Than 55, Cognitive Impairment, Others

      25 Participants Needed

      LY3209590 for Type 2 Diabetes in Children

      Louisville, Kentucky
      The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:10 - 17

      Key Eligibility Criteria

      Disqualifiers:Severe Hypoglycemia, Renal Impairment, Malignancy, Others
      Must Not Be Taking:Glucocorticoids

      22 Participants Needed

      Enhanced DPP-GLB for Weight Loss Nonresponders

      Louisville, Kentucky
      This study seeks to establish the efficacy of identifying weight loss nonresponders early in a Diabetes Prevention Program (DPP) intervention in 20 community settings (primarily churches and community centers) and providing them with individual-level, enhanced treatment through telephone contacts and access to additional resources. Additionally, potential mediators and moderators of the relationship between intervention status and weight loss response at 6 months in both nonresponders and responders will be examined and a cost-effectiveness analysis to evaluate the cost of the intervention will be conducted. This study addresses key gaps in the literature about the weight loss effects of identifying nonresponders early and characterizing individuals who need more intense personalized strategies. The investigators hypothesize that changes between baseline and 3 months will be more pronounced among the nonresponders in the intervention group compared to the nonresponders in the active control group.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Pregnancy, Serious Medical Condition, Others

      403 Participants Needed

      Inhaled Insulin for Diabetes in Children

      Louisville, Kentucky
      This trial tests an inhalable insulin called Afrezza, combined with a long-acting insulin, in children and teenagers with diabetes. Afrezza helps lower blood sugar quickly after eating, and the long-acting insulin keeps it stable all day. The study aims to see if this combination is safe and effective.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:4 - 17

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      319 Participants Needed

      Why Other Patients Applied

      "I've been in pain for years. It's been crippling and has massively impacted my life. I want to be free. Diabetes changed everything at 15. Diabetic Type 1 for 20 years. SEVERE Peripheral Neuropathy onset 7-8 years in. Have been living with it since. Have tried every drug, everything. Gaba, lyrica, all opioids, electrical current therapy, massages, acupuncture, cupping, everything. Currently taking low dose of duloxetine, have an insulin pump but its not good enough. Want to try a cutting-edge med."

      YN
      Diabetes PatientAge: 35

      "I have struggled with weight management after having bariatric surgery over 5 years ago and have regained what I have lost. I'm looking to participate in a trial that can help me get my life back under control."

      IJ
      Diabetes PatientAge: 25

      "I have had type 2 diabetes for some time now and would love to be part of a study... should the study drug work out as a successful treatment, then I would be glad to be one of the first patients in line!"

      MB
      Diabetes PatientAge: 67

      "Years ago, Metformin didn't help. I'm currently on Rybelsus & Farxiga. Not doing me much good. My insurance won't cover any of the injectables. Excited to try something new."

      QL
      Diabetes PatientAge: 71

      "I have already lost part of a leg to an infection. I want to try to get this horrific condition under control and get back to my life. It's taken enough."

      WY
      Diabetes PatientAge: 40
      Match to a Diabetes Trial

      Oral Semaglutide for Type 2 Diabetes in Youth

      Louisville, Kentucky
      This trial is testing a new diabetes medicine called semaglutide. It focuses on children and teenagers with type 2 diabetes to see if the new medicine is safe and effective. Semaglutide helps control blood sugar levels, which is crucial for managing diabetes. It has been shown to improve blood sugar control and promote weight loss in patients with type 2 diabetes.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:10 - 18

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, MODY, Others
      Must Be Taking:Metformin, Basal Insulin

      132 Participants Needed

      Baricitinib for Type 1 Diabetes

      Louisville, Kentucky
      The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 3
      Age:1 - 35

      Key Eligibility Criteria

      Disqualifiers:Other Diabetes, Heart Disease, Stroke, Others

      150 Participants Needed

      Weekly vs Daily Insulin for Type 1 Diabetes

      Louisville, Kentucky
      This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. The study will last for about 8.5 months.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Hypoglycaemic Unawareness, Others
      Must Be Taking:Insulin

      877 Participants Needed

      Dulaglutide for Type 2 Diabetes

      Louisville, Kentucky
      The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:10 - 17

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Severe Hypoglycemia, Others
      Must Be Taking:Metformin, Basal Insulin

      55 Participants Needed

      JAK Inhibitors for Type 1 Diabetes

      Louisville, Kentucky
      This trial is testing two medications, abrocitinib and ritlecitinib, which aim to reduce immune system activity. The study focuses on people who have been recently diagnosed with Stage 3 Type 1 Diabetes. These medications work by calming the immune system to prevent it from attacking insulin-producing cells in the pancreas.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:12 - 35

      Key Eligibility Criteria

      Disqualifiers:Infections, Cancer, Heart Disease, Others
      Must Not Be Taking:Immunosuppressants, Biologics, Steroids, Others

      78 Participants Needed

      Ladarixin for Type 1 Diabetes

      Louisville, Kentucky
      This trial is testing ladarixin, a medication that may help protect insulin-producing cells in the pancreas. It targets adolescents and adults who have been diagnosed with type 1 diabetes, especially those with severe cases. The goal is to see if ladarixin can slow down the progression of the disease and keep these cells working longer.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:14 - 45

      Key Eligibility Criteria

      Disqualifiers:Type 2 Diabetes, Renal Impairment, Hepatic Dysfunction, Cardiovascular Disease, Others
      Must Not Be Taking:Antidiabetics, Immunosuppressives

      140 Participants Needed

      Inhaled Insulin for Type 1 Diabetes

      Louisville, Kentucky
      This investigator-initiated study will enroll about 30 adults 18 to 65 years of age with type 1 diabetes (T1D) who are using the Tandem t:slim X2 insulin pump or Tandem Mobi insulin pump with Control-IQ or Control-IQ+ technology ("Control-IQ" which will refer to either Control-IQ or Control-IQ+). The study is being done to find out if inhaled insulin given for a meal is safer and better to use than a bolus of insulin through your pump when you exercise following a meal. Participants are asked to complete three study exercise visits in the clinic.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Asthma, Smoking, Pregnancy, Others
      Must Be Taking:Insulin

      30 Participants Needed

      Hope App for Type 2 Diabetes

      Louisville, Kentucky
      This research study will test how a computer program (called the Hope App) teaches diabetes care skills for older adults with diabetes. The study will compare those who receive diabetes education (10 educational modules and monthly health coaching) through the research program with those who receive care as usual.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:65+

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Dialysis, Pregnancy, Others

      150 Participants Needed

      Resistance Training for Type 1 Diabetes

      Louisville, Kentucky
      The purpose of this study is to learn how different resistance training programs affects blood sugar in young athletes with T1DM.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:13 - 17

      Key Eligibility Criteria

      Disqualifiers:Physical Limitations, Non-English-speaking

      15 Participants Needed

      DMR for Type 2 Diabetes

      Louisville, Kentucky
      The Revita® system is being investigated to assess the efficacy of DMR versus Sham on improvement in Glycemic, Hepatic and Cardiovascular endpoints for patients with Type 2 Diabetes who are inadequately controlled on one or more glucose lowering agents. The purpose of this study is to demonstrate the efficacy and safety of the Fractyl DMR Procedure using the Revita® System compared to a sham. Subjects randomized to the DMR procedure will be followed per protocol till 48 weeks post treatment. Subjects in the Sham treatment arm will be offered cross over to receive the DMR treatment at 48 weeks and will be followed per protocol for 48 weeks post treatment.

      Trial Details

      Trial Status:Recruiting
      Age:21 - 70

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      320 Participants Needed

      12345

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Popular Searches

      By Condition

      Depression Clinical Trials in Indiana

      Anxiety Clinical Trials in Indiana

      Schizophrenia Clinical Trials in Indiana

      ADHD Clinical Trials in Indiana

      Bipolar Disorder Clinical Trials in Indiana

      Multiple Sclerosis Clinical Trials in Indiana

      Autism Clinical Trials in Indiana

      Treatment Resistant Depression Clinical Trials in Indiana

      Borderline Personality Disorder Clinical Trials in Indiana

      Social Anxiety Disorder Clinical Trials in Indiana

      Parkinson's Disease Clinical Trials in Indiana

      Alzheimer's Disease Clinical Trials in Indiana

      By Location

      Clinical Trials near Indianapolis, IN

      Clinical Trials near South Bend, IN

      Clinical Trials near Fort Wayne, IN

      Clinical Trials near Evansville, IN

      Clinical Trials near Elkhart, IN

      Clinical Trials near Mishawaka, IN

      Clinical Trials near Michigan City, IN

      Clinical Trials near Richmond, IN

      Clinical Trials near Carmel, IN

      Clinical Trials near Lafayette, IN

      Clinical Trials near Munster, IN

      Clinical Trials near Muncie, IN

      Other People Viewed

      By Subject

      Top Diabetes Clinical Trials

      Top Gestational Diabetes Clinical Trials

      Top Pre Diabetes Clinical Trials

      Top Diabetes Clinical Trials near Seattle, WA

      Top Diabetes Clinical Trials near Plano, TX

      Top Diabetes Clinical Trials near Miami, FL

      Top Diabetes Clinical Trials near Tampa, FL

      Top Diabetes Clinical Trials near Wilmington, NC

      Top Diabetes Clinical Trials near Atlanta, GA

      Top Diabetes Clinical Trials near Houston, TX

      Top Diabetes Clinical Trials near Orlando, FL

      Top Diabetes Clinical Trials near Springfield, IL

      By Trial

      Diabetes Self-Management Program for Type 2 Diabetes

      IcoSema for Type 2 Diabetes

      Personalized Nutrition Therapy for Type 2 Diabetes

      Continuous Glucose Monitoring for Type 2 Diabetes

      Metformin + Glipizide for Diabetes

      Meal Strategies for Type 1 Diabetes

      RESET Liner for Type-2 Diabetes and Obesity

      Stem Cell Therapy for Type 1 Diabetes

      Diabetes Screening for Early Detection of Pancreatic Cancer

      Continuous Glucose Monitoring for Prediabetes

      Nutritional Intervention for Gestational Diabetes

      Lu-DOTATATE for Neuroendocrine Cancer

      Related Searches

      Top Diabetes Clinical Trials near Fort Lauderdale, FL

      Top Diabetes Clinical Trials near Fort Worth, TX

      Top Diabetes Clinical Trials near Honolulu, HI

      Top Diabetes Clinical Trials near Houston, TX

      Top Diabetes Clinical Trials near Las Vegas, NV

      Top Diabetes Clinical Trials near Los Angeles, CA

      Top Diabetes Clinical Trials near Miami, FL

      Top Diabetes Clinical Trials near Newport News, VA

      Top Diabetes Clinical Trials near New York, NY

      Top Diabetes Clinical Trials near Orlando, FL

      Top Diabetes Clinical Trials near Plano, TX

      Top Diabetes Clinical Trials near Provo, UT

      Frequently Asked Questions

      How much do Diabetes clinical trials in Evansville, IN pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Diabetes clinical trials in Evansville, IN work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Diabetes trials in Evansville, IN 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Evansville, IN for Diabetes is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Evansville, IN several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Diabetes medical study in Evansville, IN?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Diabetes clinical trials in Evansville, IN?

      Most recently, we added Adalimumab + Verapamil for Type 1 Diabetes, Percutaneous Electrical Nerve Field Stimulation for Gastroparesis and Baricitinib for Type 1 Diabetes to the Power online platform.

      What is the best treatment for diabetes?

      There isn’t one “best” therapy—think of diabetes care as two layers. First, everyone benefits from diabetes education, a balanced diet, regular activity, and routine monitoring. Second, medicines are chosen by diabetes type and other health issues: type 1 always needs insulin (preferably with a continuous glucose monitor or hybrid pump), while type 2 usually starts with metformin plus lifestyle changes and, if more help is needed, adds a GLP-1 or SGLT2 drug (especially when heart, kidney, or weight problems exist) before considering insulin. Work with your healthcare team to revisit these steps every few months so treatment keeps pace with your goals and any new health changes.

      How much weight do you need to lose to reverse type 2 diabetes?

      Most studies find that you need to shed about 10–15 % of your starting weight—roughly 15 kg (33 lb) for an average-sized adult—to give yourself the best shot at putting type-2 diabetes into remission (normal sugars without diabetes pills). The closer you are to diagnosis and the more weight you keep off—especially if you can pass the 15 kg mark—the higher the odds (up to 80 % in some trials), while smaller losses still improve blood sugar but rarely achieve full remission. Work with your healthcare team to choose a safe approach (intensive diet program, GLP-1 medications, or bariatric surgery) and to monitor that blood-sugar targets stay on track once the weight comes off.

      Can diabetics still get Ozempic?

      Yes—if you have type-2 diabetes and meet NICE criteria (poor glucose control despite other drugs, or need for weight loss/heart-protection), your GP or diabetes nurse can still prescribe Ozempic; it is not used for type-1 diabetes, pregnancy, or in children. The practical hurdle is the current UK supply shortage, so existing users should order repeats early and stay in touch with their pharmacist, while new patients may need to start a similar medicine (e.g., dulaglutide) until stock returns.

      When will oral insulin be available?

      No insulin pill has been approved yet. The most advanced candidates (such as insulin tregopil and ORMD-0801) are still redesigning or preparing large Phase 3 studies, and newer “chocolate-capsule” nano-formulations have not even begun human trials until at least 2025. If upcoming studies succeed, regulatory review and manufacturing mean that everyday prescription use is unlikely before the late-2020s at the earliest.

      Why is type 2 diabetes not curable?

      Type 2 diabetes isn’t considered curable because its root problems—body-wide insulin resistance and gradual loss of insulin-producing β-cells—can return whenever weight or lifestyle slips, and adult β-cells don’t fully regrow once lost. Big, sustained weight loss (through diet, bariatric surgery, or powerful medications) can put the disease into remission for years, but the underlying susceptibility remains, which is why regular follow-up and healthy habits must continue even when blood sugar is normal.

      Can I stop taking metformin when my sugar is back to normal?

      Normal readings don’t necessarily mean diabetes is cured; for many people the numbers stay normal only because metformin is on board, and stopping it without a plan can let sugars creep back up. Talk with your clinician about whether you truly meet “remission” criteria (HbA1c < 6.5 % for at least 6 months, stable weight, good kidney function); if so, you can try a monitored dose-reduction, check home glucose and repeat labs in 3 months, and restart the drug promptly if levels rise. In short, never quit metformin on your own—make it a shared, step-by-step decision that includes a taper and clear follow-up.

      Can a person fully recover from diabetes?

      Type 1 diabetes cannot presently be cured; people need lifelong insulin. In type 2 diabetes, some individuals—especially soon after diagnosis—can achieve remission (normal blood-sugar readings without diabetes medicines) through substantial, sustained weight loss or bariatric surgery, but the underlying tendency can return, so regular check-ups remain essential. So while you may control or even “switch off” type 2 diabetes for a time, no form of diabetes is considered permanently gone.

      Which country has the cure for diabetes?

      No country has an approved, take-home “cure” for diabetes; the Chinese cell-therapy result you may have seen was a one-patient, early-stage experiment that still needs larger trials and regulatory review. Worldwide teams—from China to the United States, Canada, Europe and beyond—are testing stem-cell implants, gene editing and immune therapies, but for now the proven way to stay healthy is tight glucose monitoring, modern medications (e.g., metformin, GLP-1 or insulin) and lifestyle changes, with bariatric surgery offering remission for some people with type 2 diabetes. Stay alert for peer-reviewed trial results and discuss any experimental option with your diabetes specialist before pursuing treatment abroad.

      What is the record trial for diabetes?

      RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes) was a 5-year study of 4,458 adults with type 2 diabetes that compared adding rosiglitazone to metformin or a sulfonylurea versus the standard metformin-plus-sulfonylurea combination. It showed no overall difference in cardiovascular deaths or hospitalisations (hazard ratio 0.99), but rosiglitazone roughly doubled the risk of heart-failure events and increased bone fractures; these safety concerns, rather than glucose control, ultimately led regulators and doctors to curb use of the drug.

      What is the A1C goal for a 70 year old?

      For a 70-year-old who already has diabetes, guidelines use a sliding scale: aim below about 7–7.5 % if the person is otherwise healthy and independent, below 8 % if they have multiple illnesses or mild functional decline, and up to 8.5 % if they are frail or in long-term care—these higher limits reduce the risk of dangerous low-blood-sugar episodes. If the 70-year-old is only being screened, the usual cut-offs still apply (normal < 5.7 %, pre-diabetes 5.7-6.4 %, diabetes ≥ 6.5 % confirmed). Work with the healthcare team to choose the target that balances day-to-day safety with long-term benefit.